PITTSBURGH, Jan. 7 /PRNewswire/ -- Cohera Medical, Inc., a rapidly growing medical device company developing a suite of wound management systems and surgical adhesives, announced today that it has expanded its executive management team with the appointment of Chad Coberly as Vice President of Clinical, Regulatory and Legal Affairs. Mr. Coberly has more than 15 years of experience in the medical device industry, primarily in the areas of regulatory/clinical affairs, compliance, quality systems, intellectual property, business development, litigation and general legal affairs. He brings experience from the law firm of Howard and Howard, the Surgical Group of the Stryker Corporation, and most recently Zassi Medical Evolutions where he served as the Vice President of Legal and Regulatory Affairs.
“Chad brings extensive domain-specific knowledge and industry experience to our company,” said Mr. Patrick Daly, President and CEO of Cohera Medical. “In addition to his regulatory expertise, he has published articles in Food and Drug Law Institute publications and has held board-level positions with Medical Device Associations. We are fortunate to have him as a member of our growing team.”
Mr. Coberly holds a J.D. from Michigan State University and a bachelor’s degree in biomedical engineering from Tulane University. He also has completed MBA studies at Boston University. He is admitted to practice before the U.S. Patent and Trademark Office and is a member of the Michigan Bar.
Cohera has also formalized its Clinical Advisory Board, which includes the following world renowned surgeons and scientists:
Cornell University
“Cohera has attracted quite a prestigious group of advisors to provide expert feedback on our efforts in new product development,” said Mr. Daly. “We look forward to working with them to create products that will continue to revolutionize the practice of surgery in all disciplines.”
About Cohera Medical, Inc.
Cohera Medical, Inc. is developing a revolutionary line of wound management products and surgical adhesives. Our products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. Our lead product in development, TissuGlu(TM) Wound Management System, is a sprayable bonding agent for plastic surgery procedures. TissuGlu(TM) adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Pre-clinical testing has shown that TissuGlu(TM) virtually eliminates seroma formation, one of the most common complications of abdominoplasty procedures. Cohera is also developing additional surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. TissuGlu(TM) and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the US or by any other country’s regulatory authority.
CONTACT: Dottie Clower, PhD, Vice President of Business Development and
Operations of Cohera Medical, Inc., +1-412-231-1500, dclower@coheramed.com;
or Lynn M. Brusco of the Pittsburgh Life Sciences Greenhouse,
+1-412-770-1353
